LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Inari Medical to Present at Upcoming Investor Conferences

August 24, 2023 | Last Trade: US$38.42 0.35 0.92

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

  • 2023 Wells Fargo Healthcare Conference
    Presenting on Friday, September 8, 2023 at 8:45 a.m. Eastern Time in Boston, MA at the Encore Boston Harbor
  • 21st Annual Morgan Stanley Global Healthcare Conference
    Presenting on Monday, September 11, 2023 at 10:40 a.m. Eastern Time in New York, NY at the Sheraton New York
  • 2023 Baird Global Healthcare Conference
    Presenting on Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time in New York, NY at the Intercontinental New York Barclay

The live audio webcasts and replays of the presentations may be accessed on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

Investor Contact:

John Hsu, CFA
VP, Investor Relations
949-658-3889
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB